Category - Feature

Feature

Launchit Solutions enhancing patient outcomes through strategic partnerships and advanced medical programs

Launchit Solutions is leveraging breakthrough technology and clinically validated innovations to bring effective healthcare solutions to patients, with a focus on obesity management, support programs, life science...

June 17, 2025

Feature

Arrivo developing novel medicines to target hard-to-treat diseases at their source

Closely-held Arrivo BioVentures is developing novel, first-in-class medicines that target the underlying causes of diseases with high unmet need, aiming to achieve meaningful patient outcomes that extend and improve the...

June 10, 2025

Feature

JVP Labs redefining congestive heart failure monitoring

Closely held JVP Labs is developing the only non-invasive, real-time cardiac filling pressure monitoring solution for managing congestive heart failure (CHF) patients—for both in the hospital and at home.

June 3, 2025

Feature

Eledon leading a paradigm shift in immunosuppression therapy in organ transplantation

Eledon Pharmaceuticals (NASDAQ: ELDN) is pioneering a potential breakthrough in immunosuppression therapy aimed at extending the longevity of transplanted organs and enhancing the overall health and quality of life for...

May 27, 2025

Feature

Longhorn impacting global health challenges by tackling bacterial toxins with vaccine and diagnostics solutions

Closely held Longhorn Vaccines and Diagnostics is developing peptide vaccines and monoclonal antibodies aimed at preventing and reducing the global burden of medical conditions caused by key bacterial toxins, including...

May 20, 2025

Feature

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Terns Pharmaceuticals (NASDAQ:TERN) is developing a portfolio of novel, oral small-molecule product candidates based on clinically validated mechanisms of action to address serious diseases including oncology and...

May 6, 2025

Feature

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

April 29, 2025

Feature

Arch advancing game-changing therapies for global kidney care

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

April 15, 2025

Feature

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...

April 1, 2025

Feature

Vivos transforming the lives of patients with obstructive sleep apnea

Vivos Therapeutics (NASDAQ:VVOS) is developing and commercializing innovative diagnostic and treatment methods for adult and pediatric patients suffering from sleep-related breathing disorders, including severe...

March 25, 2025

Category - Feature

Subscribe